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Purpose: To evaluate the efficacy of levetiracetam in cases of refractory primary generalised epilepsy.
Methods: Three patients with refractory primary generalised epilepsy were treated with levetiracetam monotherapy; one with
absence seizures, myoclonic jerks and generalised tonic–clonic (GTC) seizures one with myoclonic jerks and GTC seizures, and
one with only GTC seizures. All three patients had generalised spike wave on the EEG and had failed at least three antiepileptic
drugs (AEDs) before trying levetiracetam.
Results: All three patients tolerated levetiracetam well and became seizure free for at least 6 months. Therapeutic doses of
levetiracetam ranged from 1250 to 3000 mg/day.
Conclusion: Levetiracetam, a new AED with a novel mechanism(s) of action, should be considered for patients with refractory
primary generalised epilepsy.
© 2002 BEA Trading Ltd. Published by Elsevier Science Ltd. All rights reserved.
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INTRODUCTION
Conventional treatment for primary generalised epi-
lepsy includes valproic acid and more recently, lam-
otrigine and topiramate1. Because carbamazepine,
gabapentin, phenytoin, tiagabine and vigabatrin may
aggravate absence seizures or myoclonic jerks, their
role in primary generalised epilepsy is limited2.
Three patients with primary generalised epilepsy
refractory to other antiepileptic drugs (AEDs) were
treated with levetiracetam monotherapy (Table 1).
Levetiracetam received US Food and Drug Admin-
istration (FDA) approval in November 1999 as ad-
junctive treatment for partial onset seizures in adults
based on three multicentre, randomised, double-blind,
placebo-controlled clinical studies in 904 patients
with refractory partial seizures with or without sec-
ondary generalisation for at least 2 years3–5. The
number of patients who achieved a seizure reduction
of at least 50% compared to baseline was 28.6% of
patients on 1000 mg/day, 35.2% on 2000 mg/day and
39.5% on 3000 mg/day6. Adverse events included
somnolence (14.8%), asthenia (14.7%), infection
(13.4%), behavioural problems (13.3%), dizziness
(8.8%), pharyngitis (6.1%) and rhinitis (4.4%)7. The
majority of adverse events were mild to moderate.
Since these pivotal trials, over 100 000 patients in the
US have been treated with levetiracetam8.
Case #1
MS was a 15-year-old left-handed boy whose seizures
began with a convulsion at age 12. While awake but
sleep deprived, he had two more convulsions a few
months later prompting him to seek medical atten-
tion. His family history was notable for a brother with
seizures that began at age 3 and resolved at age 13.
MS had no history of myoclonic jerks or staring spells.
Development, neurological examination, CT and brain
MRI were normal. His first EEG was normal; how-
ever, the second revealed frequent bursts of 2–3 Hz
generalised spike and wave lasting up to 15 seconds.
MS began treatment with carbamazepine 100 mg
b.i.d. Over the first year, he had several convulsions,
often associated with non-compliance. He switched
to delayed release carbamazepine (Carbatrol), 300 mg
b.i.d., and had trough levels of 8.6g/ml. He con-
tinued to have occasional breakthrough seizures and
divalproex sodium was substituted for carbamazepine.
At levels of 120g/ml, he was seizure free, but
complained of fatigue and hepatic enzymes were
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Table 1: Clinical information and results of levetiracetam treatment.
Patient ID Patient age Failed AEDs Seizure Type(s) EEG results Levetiracetam starting Levetiracetam maintenance Adverse effects Months seizure- free
(years) dose (mg b.i.d.) dose (mg b.i.d.) of levetiracetam
MS 15 CBZ, TPM, VPA GTC 2–3 Hz generalised
spike per wave
250 1500 None >9
RR 26 CBZ, LTG, PB,
PHT, VPA
Absence, GTC,
myoclonic jerks
3.5–5.5 Hz generalised
spike per wave
250 1000 None >9
SS 61 FBM, LTG, TPM,
PHT, VPA
GTC, myoclonic
jerks
Generalised spike per
wave fragments
250 625 Early morning
fatigue on 750 mg
b.i.d.—resolved
on 625 mg b.i.d.
>6
CBZ, carbamazepine; FBM, felbamate; GTC, generalised tonic–clonic; LTG, lamotrigine; PB, phenobarbital; PHT, phenytoin; TPM, topiramate; VPA, divalproex sodium.
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slightly elevated, aspartate aminotransferase (AST)
120 Karmen units (0–34) and alanine aminotrans-
ferase (ALT) 93 Karmen units (0–40).
The patient developed a viral syndrome, and was
unable to take the valproate. His valproate level
dropped to 50g/ml, and he developed generalised
tonic–clonic (GTC) status epilepticus. Divalproex
sodium was tapered and he began topiramate. Dosages
were increased to 200 mg b.i.d. The patient com-
plained of fatigue and cognitive slowing. Topiramate
was tapered and he started levetiracetam at 250 mg
b.i.d., which was increased to 1500 mg b.i.d. He has
been seizure free for 9 months since beginning lev-
etiracetam and is back to normal school and sports
activity.
Case #2
RR was a 26-year-old right-handed man who had his
first GTC seizure during sleep at age 3. At age 5,
he had a convulsion while awake and was placed on
phenobarbital. During childhood, he developed ab-
sence seizures. Myoclonic jerks appeared during high
school. His last convulsion occurred when he was a
teenager. His family history was notable for absence
seizures in both his sister and mother.
Physical and neurological examinations were un-
remarkable. Brain MRI was normal, but an EEG re-
vealed atypical generalised spike wave (3.5–5.5 Hz).
Treatment with carbamazepine was associated
with GTC status epilepticus. Seizures were con-
trolled with divalproex sodium, but he developed a
macular–papular, pruritic rash forcing discontinuation
of the divalproex sodium.
Treatment with phenytoin 300 mg/day and pheno-
barbital 100 mg/day controlled his convulsions, but
he continued to have occasional absences and suf-
fered cognitive side effects. He also took sertraline
100 mg/day for depression. Phenytoin was discontin-
ued and the patient began lamotrigine. Lamotrigine
was increased to 200 mg b.i.d. and phenobarbital was
tapered over the next 6 months. He began to feel
jittery and received lorazepam. He developed my-
oclonic jerks, and was switched from lamotrigine to
levetiracetam 250 mg b.i.d. titrated up to 1000 mg
b.i.d. Lorazepam was no longer needed after the pa-
tient became stabilised on levetiracetam. He has had
no more absences, myoclonic jerks or convulsions for
the last 9 months.
Case #3
SS was a 61-year-old right-handed man who devel-
oped myoclonic jerks and convulsions upon awaken-
ing at age 16. Family history was negative for seizures.
Convulsions have been infrequent, the last one over 10
years ago. However, he continued to have myoclonic
jerks and complained of decreased libido.
Physical and neurological examinations were nor-
mal except for coarsening of facial features and pro-
longation of end gaze nystagmus. Brain MRI showed
mild leukoencephalopathy, likely due to microvascu-
lar disease. Rare fragments of generalised spike wave
were present on the EEG.
Phenytoin at 400 mg/day produced a trough level
of 19, but did not control the myoclonus, nor did di-
azepam 5 mg p.r.n. Divalproex sodium succeeded in
eliminating all seizure types, but resulted in a 15 lb
weight gain, which could not be corrected with diet.
Divalproex sodium also produced persistent abdom-
inal pain, unrelieved by antacids, histamine blockers
or switching to Depakote Sprinkles. Felbamate caused
muscle weakness. He tried topiramate, but developed
cognitive side effects at the initial dose of 25 mg/day.
He switched to lamotrigine and initially felt better,
but a maximal dose of 250 mg b.i.d. failed to control
the myoclonic jerks. Finally, he tried levetiracetam at
a starting dose of 250 mg b.i.d. This was titrated up
to 750 mg b.i.d. as the lamotrigine was tapered and
discontinued. Because he complained of early morn-
ing fatigue, the levetiracetam was decreased to 625 mg
b.i.d. He had no cognitive complaints, further my-
oclonic jerks or other seizure types. In fact, he de-
scribed levetiracetam as ‘the best of the lot’ of all
the antiepileptic medications that he has tried. He has
been seizure free for over 6 months.
DISCUSSION
These three patients with refractory primary gener-
alised epilepsy became seizure free when levetirac-
etam was added to their treatment regimen. Effective
doses ranged from 1250 to 3000 mg/day. After dose
titration, all of the patients tolerated the drug well.
When patients present with convulsions, physicians
often fail to differentiate between primary generalised
epilepsy and partial seizures with secondary generali-
sation. Patients may not provide a history of myoclonic
jerks and absence attacks may pass undetected. How-
ever, the consequences of inaccurate diagnosis can be
severe, as a number of AEDs may worsen primary
generalised epilepsy2. In fact, Case #2, RR, developed
status epilepticus after treatment with carbamazepine.
Careful attention to the clinical history and EEG find-
ings often leads to an accurate classification of seizure
type. AEDs effective in partial and primary gener-
alised seizures, such as valproate, offer an advantage
in patients in whom the seizure type is unclear. Lam-
otrigine, topiramate and levetiracetam may also be
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effective in both partial and primary generalised
seizures.
Although there are no published clinical trials de-
voted specifically to levetiracetam and primary gen-
eralised seizures, a multicentre trial of 119 refractory
epilepsy patients conducted in 37 sites in the United
Kingdom and Belgium between September 1993 and
March 1997 study included patients with primary
generalised epilepsy who received levetiracetam in
doses of 2000 or 4000 mg/day. The median percentage
reduction in seizure frequency was similar between
both partial and primary generalised epilepsy treat-
ment groups13. In the US multicentre double-blind,
randomised, placebo-controlled trial, ‘7% had gen-
eralised seizures and unclassified epileptic seizures’,
but the response of this small group to treatment was
not detailed4.
Animal data also support the use of levetiracetam for
primary generalised epilepsy14. Levetiracetam admin-
istered intraperitoneally caused a long lasting increase
in the threshold for tonic electroconvulsive seizures in
mice, similar in magnitude to the effect of valproate.
Levetiracetam increased the tonic electroconvulsive
seizure threshold in rats as well. It was also effective
against myoclonic and clonic seizures induced by in-
travenous pentylenetetrazol (PTZ). Its anticonvulsant
potency against myoclonic seizures was approxi-
mately double that of valproate or ethosuximide.
Lamotrigine, levetiracetam, topiramate and val-
proate all have bioavailability that approaches 100%.
The protein binding of levetiracetam is <10%, while
it is 55% for lamotrigine, 15% for topiramate and
85–95% for valproate9. Unlike lamotrigine, topira-
mate and valproic acid, levetiracetam does not interact
with other AEDs and only levetiracetam has no ef-
fect on hepatic enzymes. Another practical advantage
of levetiracetam compared to lamotrigine and topi-
ramate is that it can be started at a therapeutic dose
of 1000 mg/day3. Levetiracetam can be increased to
3000 mg/day within 4 weeks10.
The effects of lamotrigine, levetiracetam, topiramate
and valproate on the unborn foetus are currently un-
known. All of these drugs are ‘Category C’, except
for valproate, which is ‘Category D’. Valproate ‘is
associated with the highest rate of major congenital
abnormalities’ of all commonly used AEDs11. Terato-
genicity is a significant consideration in the popula-
tion of patients with primary generalised epilepsy, as
many are women of childbearing potential.
Topiramate has been associated with renal lithiasis
(1.5%), cognitive effects and speech difficulty12. Like
lamotrigine, it also requires slow titration, and can take
weeks to months to achieve the desired dosage.
Limitations of this study include the open label
design and small patient population. However, all
patients had failed at least three AEDs and had
well-documented clinical and EEG evidence of pri-
mary generalised epilepsy. The successful treatment
of these three patients suggests that levetiracetam
monotherapy may be a safe and effective choice for
patients with primary generalised epilepsy, particu-
larly those refractory to other AEDs. Given these pos-
itive responses and the attractive side-effect profile,
lack of drug–drug interactions, low protein binding
and prompt efficacy at starting doses, a prospec-
tive, controlled clinical trial of levetiracetam in pa-
tients with primary generalised epilepsy should be
considered.
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